Immune globulin (human) is a Antibody and Blood Derivative owned by ADMA Biologics, and is involved in 11 clinical trials, of which 8 were completed, and 3 are ongoing.

RI-002 (Immune globulin (human)) is a plasma-derived, polyclonal, intravenous immune globulin (IGIV) derived from human plasma containing naturally occurring polyclonal antibodies as well as high levels of antibodies targeted to RSV. Polyclonal antibodies produced by B-cells neutralize microbes such as bacteria and viruses and may prevent infections.

The revenue for Immune globulin (human) is expected to reach a total of $1.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Immune globulin (human) NPV Report.

Immune globulin (human) is originated and owned by ADMA Biologics.

Immune globulin (human) Overview

Human immunoglobulin (Asceniv) contains mainly immunoglobulin G (IgG) with a broad spectrum of antibodies against various infectious agents. It is formulated as injectable solution for intravenous route of administration. Asceniv is indicated for the treatment of  for the treatment of immune deficiencies and the prevention of certain infectious diseases administered in adults and adolescents patients of 12 to 17 years of age.

RI-002 is under development for the treatment of respiratory syncytial virus (RSV) infections. The drug candidate is administered intravenously. Immunoglobulin (also called gamma globulin or immune globulin) is a substance made from human blood plasma. The plasma, processed from donated human blood, contains antibodies that protect the body against diseases. Polyclonal antibodies are the primary component of IGIV products. Intravenous immune globulin (Human) contains immune globulins extracted from source plasma through a manufacturing process called fractionation.

ADMA Biologics Overview

ADMA Biologics is an integrated biopharmaceutical and specialty immunoglobulin company which develops, produces, and commercializes specialty biologics to treat immune deficiencies and prevent certain infectious diseases. The company develops Bivigam, a plasma-derived IVIG that contains a broad range of antibodies; and ASCENIV, a specialty plasma-derived, polyclonal, intravenous immune globulin, derived from human plasma containing naturally occurring polyclonal antibodies to treat Primary Immune Deficiency Disease. ADMA Biologics’ target treatment areas include bacterial infections, respiratory syncytial virus and primary immune deficiency diseases. It also operates bio centers which carry out plasma collection and offer blood plasma to manufacture the company’s products. ADMA Biologics is headquartered in Ramsey, New Jersey, the US.

The company reported revenues of (US Dollars) US$80.9 million for the fiscal year ended December 2021 (FY2021), an increase of 91.7% over FY2020. The operating loss of the company was US$58.4 million in FY2021, compared to an operating loss of US$63.9 million in FY2020. The net loss of the company was US$71.7 million in FY2021, compared to a net loss of US$75.8 million in FY2020. The company reported revenues of US$41.1 million for the third quarter ended September 2022, an increase of 21.2% over the previous quarter.

Quick View – Immune globulin (human)

Report Segments
  • Innovator (NME)
Drug Name
  • Immune globulin (human)
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Immunology
  • Infectious Disease
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.